Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Targeting <i>RAS</i> in pancreatic cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
10.3322/caac.21820
10.3322/caac.21820 · External reference
10.1016/j.cell.2023.02.014
10.1016/j.cell.2023.02.014 · External reference
10.3390/cancers17152453
10.3390/cancers17152453 · External reference
10.1101/cshperspect.a031435
10.1101/cshperspect.a031435 · External reference
Comprehensive pan‐cancer genomic landscape of KRAS‐altered cancers
10.1038/s41698-022-00334-z · 2022 · External reference
Real‐time targeted genome profiling identifies actionable alterations in KRAS wild‐type pancreatic cancer
2019 · External reference
10.1038/s41571‐022‐00671‐9
10.1038/s41571‐022‐00671‐9 · External reference
10.1056/nejmoa1011923
10.1056/nejmoa1011923 · External reference
10.1056/nejmoa1304369
10.1056/nejmoa1304369 · External reference
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer (NAPOLI‐1)
10.1016/s0140-6736(15)00986-1 · 2016 · External reference
10.1056/nejmoa1903387
10.1056/nejmoa1903387 · External reference
The role of germline testing and PARP inhibition in pancreatic cancer
2022 · External reference
Translational pharmacology of RMC‐6236, a RAS(ON) multi‐selective inhibitor
2024 · External reference
10.1038/s41586‐024‐07205‐6
10.1038/s41586‐024‐07205‐6 · External reference
10.1056/nejmoa2605555
10.1056/nejmoa2605555 · External reference
10.1056/nejmoa2505783
10.1056/nejmoa2505783 · External reference
10.1158/2159‐8290.cd‐19‐1006
10.1158/2159‐8290.cd‐19‐1006 · External reference
10.1200/jco.2026.44.16_suppl.tps4264
10.1200/jco.2026.44.16_suppl.tps4264 · External reference
10.1056/nejmoa1917239
10.1056/nejmoa1917239 · External reference
10.1056/nejmoa2208470
10.1056/nejmoa2208470 · External reference
10.1200/jco.23.00434
10.1200/jco.23.00434 · External reference
10.1158/2159‐8290.cd‐24‐0177
10.1158/2159‐8290.cd‐24‐0177 · External reference
10.1038/s41591‐022‐02007‐7
10.1038/s41591‐022‐02007‐7 · External reference
10.1021/acs.jmedchem.1c01688
10.1021/acs.jmedchem.1c01688 · External reference
10.1056/nejmoa2600752
10.1056/nejmoa2600752 · External reference
10.1038/s42004‐025‐01662‐4
10.1038/s42004‐025‐01662‐4 · External reference
10.3390/molecules28145600
10.3390/molecules28145600 · External reference
Unresolved reference
External reference
10.1158/1538‐7445.am2026‐lb337
10.1158/1538‐7445.am2026‐lb337 · External reference
10.1158/1538‐7445.am2026‐lb407
10.1158/1538‐7445.am2026‐lb407 · External reference
Safety and efficacy of zoldonrasib plus chemotherapy in patients with first‐line RAS G12D metastatic pancreatic cancer
10.1016/j.annonc.2026.05.381 · 2026 · External reference
Safety and efficacy of zoldonrasib plus daraxonrasib in patients with second‐line or later RAS G12D metastatic pancreatic cancer
10.1016/j.annonc.2026.05.382 · 2026 · External reference
10.1038/s41586‐023‐06123‐3
10.1038/s41586‐023‐06123‐3 · External reference
10.1016/j.annonc.2026.08.003
10.1016/j.annonc.2026.08.003 · External reference
Unresolved reference
External reference
10.1200/jco.20.01364
10.1200/jco.20.01364 · External reference
Pancreatic cancer: ESMO Clinical Practice Guideline
10.1016/j.annonc.2023.08.009 · 2023 · External reference
10.3389/fonc.2022.1013902
10.3389/fonc.2022.1013902 · External reference
Unresolved reference
External reference
